Frequency of Hepatitis B Markers in Systemic Lupus Erythematosus Patients in Iran

Manoochehr Makvandi1*, Sedigheh Noormandi Pour2, Ali Teimoori2, Somayeh Shokri2, Shahab Mahmoudvand2, Somayeh Biparva Haghighi3, Elham Rajaee3

Abstract

**Background:** Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Hepatitis B virus is the causative agent for chronic, acute, cirrhosis, and hepatocellular carcinoma. SLE patients with chronic or occult hepatitis B infection undergoing immunosuppressive drugs may become reactive and develop fatal hepatitis. Therefore, this study was conducted to determine HBV markers in SLE patients before the administration of immunosuppressive drugs in Ahvaz city, Iran. **Materials and methods:** The sera of 92 SLE patients were tested for HBs Ag and anti-HBc using ELISA, HBV DNA (by Nested PCR) tests. Real-time PCR was performed for the patients with positive anti-HBc and negative HBsAg. The positive HBV DNA samples were checked for HBV genotype and HBV subtypes. **Results:** Among the 92 SLE patients, three (3.3%) were males and 89 (96.7%) females. The patients’ ages ranged from 14 to 70 years [mean age of 38.9±10.1]. Three of 92 (3.26%) subjects [2/3 males and 1/89 female] were positive for HBsAg, anti-HBc Ab, and HBV DNA detected with PCR (p=0.000003). Five of 89 (5.61%) subjects [1 male and 4/88 females were only positive for anti-HBc and negative for HBs Ag, HBV DNA(PCR) using Real-time PCR (p=0.05). The results of the nucleotide data and phylogenetic tree showed all three HBV patients were genotype D1. The results of amino acid sequencing revealed all three HBV patients were HBV subtype ayw2. **Conclusion:** This study proved that 3.26% of SLE patients were positive for overt HBV infection (positive for anti-HBc, HBsAg and HBV-DNA using PCR). All the three isolated HBV were genotype D1 and subtype ayw2. The fact that 5.61% of the patients were only positive for anti-HBc characterized the occult hepatitis B infection (OBI) although further investigation is needed. To prevent HBV or OBI reactivation for SLE patients before immunosuppression treatment, HBV markers including anti-HBc, HBsAg, HBV-DNA should be implemented using PCR and Real-time PCR .

**Keywords:** Chemotherapy- nested polymerase chain reaction- systemic lupus erythematosus

**Introduction**

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease which causes inflammation and damage to tissues and organs including joints, skin, brain, lungs, kidneys, and blood vessels (Francis and Perl, 2010, Tsokos., 2011). Several factors may be implicated in SLE development including environmental, genetic, immunological alterations and infectious agents (Mu et al., 2015). Usually, the liver is not the target in SLE though 25-50% of lupus patients may have abnormal liver function throughout viral hepatitis (Bessone et al., 2014; Huang et al., 2012).

Hepatitis B virus (HBV) is a major global health problem. It is estimated that 230 million population are chronically infected worldwide (Weckerle and Niewold, 2011; Tordrup et al., 2019). The prevalence of hepatitis B infection is low (<2%) among the population in Iran (Alavian et al., 2007). No data is available to validate the prevalence of HBV infection in the Khuzestan province. The persistence and replication of HBV in hepatocytes may result in wide spectrum of liver disease such as cirrhosis, fibrosis and hepatocellular carcinoma (Dandri and Petersen ,2016; Nour et al., 2022; Radwan et al., 2022). The frequency of HBV reactivation is estimated to be about 20% to 50% in HBV carriers undergoing immunosuppressive treatment and in some cases has led to fulminant or fatal hepatitis (Lok and McMahon, 2009; Huang et al., 2014; Chenet al., 2015).

The HBV reactivation is described as levels of serum HBV DNA rising at least 10 times (compared to baseline) and (ALT level ≥3-fold increases compared to baseline >100 U/L) (Patel et al., 2015; Paul et al., 2015). The reactivation of occult hepatitis B infection (OBI)
in patients with autoimmune diseases who underwent immunosuppressive drugs resulted in fulminant hepatitis (Matsumoto et al., 2016; Chen et al., 2020). OBI is defined by the detection of HBV DNA liver tissue/or in serum of HBsAg negative subjects. The level of HBV-DNA in the serum is usually low (<200 IU/mL or 1,000 copy number/mL) (Kwak et al., 2014).

Two classes of OBI are described as seropositive and seronegative. Seropositive OBI refers to the presence of anti-HBc and/or anti-HBs in the serum but HBV DNA is detected in serum/liver. While seronegative OBI refers to when both anti-HBc and anti-HBs are negative in the serum but HBV DNA is detected in serum/liver. To determine OBI, the liver biopsy requires as a gold standard for detection of HBVDNA (Makvandi, 2016). The detection of anti-HBc alone in the blood is reported to be used as a surrogate marker to identify OBI (Raimondo et al., 2019). Similarly, the detection of anti-HBc alone was reported in some blood donors with OBI who had undetectable HBV DNA by NAT (nucleic acid testing) (Spreafico et al., 2015). HBV reactivation has been described in individuals negative HBsAg, positive anti-HBc who had undetectable HBV DNA in the blood (Cholongitas et al., 2018). The detection of OBI can be achieved by highly sensitive methods such as real-time PCR and nested-PCR (Raimondo et al., 2008; Sosa-Jurado et al., 2018). Therefore, this study was conducted to determine the frequency of HBV infection in SLE patients in Ahvaz city. Ahvaz is the capital of Khuzestan province and is located at Southwest region of Iran.

Materials and Methods

Patients: In this cross-sectional study, 92 (including 89 females and 3 males) consecutive patients with diagnosed SLE were selected in Golestan Hospital during January 2017 to December 2017. The rheumatology ward of Golestan hospital of Ahvaz city is a referral center for the Khuzestan province (totally about 5 million population) and neighboring provinces for all treatment procedures. The patients’ ages ranged from 14 to 70 with a mean age of 38.9±10.1 years. 3/92 (3.3%) of patients were males and 89/92 (96.7%) were females. The SLE was diagnosed according to the American College of Rheumatology (ACR) revised criteria for the classification of systemic lupus erythematosus (Hochberg MC, 1997). The inclusion criterion required untreated diagnosed SLE patients. The exclusion criteria were rheumatoid arthritis, systemic sclerosis (scleroderma), vasculitis, dermatomyositis, and arthritis. Underlying malignancy, recognized chronic infection (e.g., human immunodeficiency virus, Endocarditis, osteomyelitis), or pregnancy. Their blood and sera were tested for the following criteria. The clinical and immunological criteria of SLE patients are presented in Table 1. ESR level was 47±28 (mm/hour) and CRP level was 7.2 ± 5.1 (mg/dl).

Molecular Tests

The patients’ sera were approved positive for HBsAg, anti-Hbc Ab and HBV DNA using Nested PCR. The SLE patients proved positive for anti-HBc Ab but negative for HBsAg and HBV DNA using Nested PCR and also tested by Real time PCR.

DNA extraction

DNA was extracted from specimens using High Pure Viral Nucleic Acid Kit (Roche, Germany) according to manufacturer’s instructions. The extracted DNA was stored at -20°C until used for further analysis.

Nested PCR

For the first round PCR, the following outer primers, FHBS1: 5′-GAGTCTAGACTCTGGTGGAATTC-3′ (nt. 246–269) and RHBBS1: 5′-AAAA TKGCACTAGTTAAACTGAGCCA-3′ (nt. 670–693) were used (Sitnik et al., 2004). The PCR reaction mixture contained 7 µl 400 ng of isolated DNA sample as template, 2.5 µl 10x reaction buffer, 0.75 µl MgCl2 (50 mM), 0.5 µl forward/reverse primer, 1 µL dNTP (10 mM), 0.2 Cinna Gen Taq DNA Polymerase (5 u/µl), and double-distilled water up to 25 µl. The reaction mixture was subjected to thermal cycler (TC-512, Technie, Staffordshire, UK) with the following program: 1 cycle with initial denaturation at 94°C for 5 minutes, followed by 35 cycles, 94°C for 1 minute, 60°C for 1 minute, 72°C for 2 minutes, and final extension at 72°C for 10 minutes. For the second round, following inner primers, FHBS2: 5′-CGTGTTGGAACCTTCTCATAATTTTC-3′ (nt. 257–280) and RHBBS2: 5′-GCCARGAGAAACGGRCTGAGGCCC-3′ (nt. 650–673) (Sitnik et al., 2004) was used. For the second round, 5 µl PCR product of first round was added to PCR reaction mixture containing the same amount of components as described in the first round and subjected to thermal cycler. The thermal cycler was programmed as follows: initial denaturation at 94°C for 5 minutes, 30 cycles at 94°C for 1 minute, 44°C for 1 minute, 72°C for 1 minute, 1.5 minutes, and final extension at 72°C for 10 minutes. All reactions were performed in the presence of negative and positive controls.

Sequencing and Phylogenic Analyses

The positive PCR products were sent to Bioneer Company (Korea) and sequenced in two directions to determine HBV genotyping. The results of nucleotide sequencing of partial “S” region of isolated HBV were aligned using NCBI HBV database (https://blast.ncbi.nlm.nih.gov) to determine the HBV genotyping. To determine HBV subtype, the results of “a” determinant of “S” gene of isolates HBV from Ahvaz were aligned with the consensus amino acid sequence of the reference HBV D genotype using SnapGene software (3.2.1). The phylogenetic tree was constructed for each isolated partial S region by Neighbor Joining method under the Kimura 2-parameter distance model by 1000 bootstrap replicates (Studier and Keppler, 1988). The MEGA software version 6 was employed to implement the methods.

Real time PCR

To determine seropositive Occult Hepatitis B Infection (OBI). The quantitative Real Time PCR was performed for those sera positive for anti-HBc Ab but negative
for HBsAg and HBV DNA by the nested PCR. The quantitative Real Time PCR test kit (Primerdesign Ltd, UK) was used according to manufacturer’s instruction.

Ethical consent: The project was approved with ethical code IR.AJUMS.REC.1395.396 by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. All of the subjects included in the study were orally informed about the purpose of the study and invited to participate voluntarily. Written informed consent was obtained from all the patients.

Statistical analysis: Data analyses were performed using the Statistical Package for the Social Sciences 22.0 (SPSS Inc., Chicago, IL, USA). Chi-Square test was used to calculate. P<0.05 was accepted as significant.

Results

Three of 92 (3.26%) patients including 2/3 males and 1/89 female were positive for HBsAg, anti-HBc Ab and HBV DNA by nested PCR (p=0.000003). The sera of these 3 (3.26%) patients had upper limited level of ALT (43±4.0) and AST (42±8.0). The sera of 5/89 (5.61%) samples of 1 male and 4/88 females were only positive for anti-HBc but negative for HBs Ag, HBV DNA using nested PCR and Real time PCR (p=0.05) (Table 1). The sera of these 5 (5.61%) patients had upper limited level of ALT (41±43.0) and AST (40±40).

The results of partial sequences of S region of three HBV- DNA positive cases isolates from Ahvaz were recorded in GenBank with registration numbers MK886716, MK886717, and MK886718. The results of nucleotide data and amino acid sequencing and alignment of all three partial HBV DNA isolates revealed that all three samples belonged to genotype D1. The alignment of partial sequences of all three isolated HBV (MK886716, MK886717, and MK886718) showed the presence of amino acids at positions of 122R, 127P, 140T, 159G, 160K belonging to ayw2 subtype.

Determination of HBV subtypes

The analyses of partial amino acid sequences of surface (S) gene region of three isolated HBV (MK886716, MK886717, MK886718) were implemented with consensus reference (BAM75990.1). The results showed all three isolated HBV comprised of amino acids at positions 122R + 127P + 140T, 145G, 159G and 160K. All three isolates HBV were recognized as HBV subtype ayw2.

Table 1. shows the Clinical and Immunological Criteria of SLE Patients

| Clinical criteria                                      | %  |
|-------------------------------------------------------|----|
| Acute cutaneous lupus erythematosus                    | 94 |
| Chronic cutaneous lupus erythematosus                  | 33 |
| Oral ulcers                                           | 9  |
| Non-scarring alopecia                                  | 89 |
| Synovitis (≥ 2 joints)                                 | 38 |
| morning stiffness                                      | 34 |
| Serositis                                              | 28 |
| Renal involvement (24-hour urine protein, >0.5 g)      | 62 |
| Renal biopsy (nephritis)                               | 62 |
| Neurological manifestation                             | 8  |
| Hemolytic anemia                                       | 11 |
| Leukopenia (<4,000/μL)                                 | 49 |
| lymphopenia (<1,000/μL)                                | 52 |
| Thrombocytopenia (<100,000/μL)                         | 84 |

| Immunological criteria                                 | %  |
|-------------------------------------------------------|----|
| Anti-nuclear antibody                                  | 100|
| Anti-dsDNA antibodies                                  | 67 |
| Anti-Sm antibodies                                     | 8  |
| Antiphospholipid antibodies                            | 33 |
| Low complement (C3)                                    | 78 |
| Low complement (C4)                                    | 71 |
| Direct Coombs test                                     | 12 |

Results of Phylogenic trees

The results of the phylogenetic tree demonstrated that all the three HBV DNA isolations in Ahvaz (MK886716, MK886717, and MK886718) were clustered with genotype D1 isolated from Turkey (AB674418.1) (Figure 1). The results of qPCR was negative for all the 5 positive anti-HBc Ab.

Discussion

The chronic Systemic lupus erythematosus (SLE) may result in organ dysfunction over time (Francis and Perl, 2010; Tsokos, 2011). The SLE patients with HBV markers are at risk of HBV reactivation, which may lead to high morbidity and mortality rates since SLE patients need corticosteroid and immunosuppressive drugs treatment during the course of the disease (Lin et al., 2018; Kuo...
et al., 2020).

In our study, the low frequency of 3 (3.26%) samples including 2 males and one female were found positive for HBV markers, HBsAg, anti-HBc Ab and HBV DNA using nested PCR. Several studies have also reported low prevalence of HBV infection among SLE patients. Low prevalence of 2.7% HBV infection was observed in patients with SLE in China (Wang et al., 2017), 0.3% in Japan (Watanabe et al., 2014) and 1.5% (2/134) in Thailand (Sumethkul and Srivitidkul, 2017). Serological detection of “anti-HBc only” specifies exposure to HBV, lifelong persistence of cccDNA, and the risk for reactivation under strong immunosuppression (Gish et al., 2020). Presence of anti-HBc alone could be a surrogate marker for detection of OBI which indicates a significant clinical concern (Hourfar et al., 2009; Raimondo et al., 2008; Roman, 2018; Raimondo et al., 2019). The gold standard for OBI diagnosis is the detection of HBV DNA in the liver but a biopsy is not easily available (Raimondo et al., 2019). Thus, the detection of OBI is very difficult due to very low virus load and mutations in HBV genome (Candotti et al., 2019; Spreafico et al., 2015). Nonetheless, recent reports on significance of anti-HBc detection show that it can play an alternative gold standard for OBI diagnosis. In agreement with OBI, it was found that donated samples may carry anti-HBc alone which are very infectious (Allain and Cox, 2011). Even individuals with certain PCR negative “anti-HBc alone” have been shown to be potentially infectious (Akcam and Demir., 2005). A recent study revealed that blood donors negative for both HBsAg and HBV DNA but positive for anti-HBc could be HBV carriers with viral loads below the detection limit (Oluyinka et al., 2005).

Thus, the Anti-HBc screening can potentially exclude the majority of OBIs which are undetectable by NAT (Taira et al., 2013; Vermeulen et al., 2014; Seed et al., 2015). The prevalence of OBI has been reported among the patients with SLE. In Our survey, 5/89 (5.61%) SLE patients including 1 male and 4/88 females were positive for anti-HBc but negative for HBs Ag, HBV DNA using...
nested PCR and Real time PCR (p=0.05). It was reported that among 177 adults with active lupus nephritis, 68 cases were positive with OBI with undetectable HBV DNA (Fang et al., 2018). The results of phylogenetic analysis revealed that all three isolated HBV DNA (K886716, MK886717, and MK886718) were clustered with genotype D1 isolated from Turkey (AB674418.1). The alignment of partial sequences of all three isolated HBV (MK886716, MK886717, and MK886718) showed the presence of amino acids at positions of 122R, 127P, 140T, 159G, 160K and found to be of awy2 subtype. (Rahman et al 2016). The predominant genotype D and HBV serotype ayw2 have been previously reported in Iran (Haghshenas et al., 2014). The reactivation of HBV in SLE patients is a great issue and can be life-threatening. The HBV reactivation has been investigated among the SLE receiving immunosuppressive therapy with consequences such as severe flare, decompensation and death (Lin et al., 2018). Recently, 3 antiviral therapies, entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide are recommended to be used in the prophylaxis or treatment of HBV reactivation and are recommended to be given concomitantly with anticancer therapy (Terrault et al., 2018; Huang et al., 2014).

SLE patients are generally under immunosuppression and to halt HBV consequences such as reactivation, fulminant hepatitis, cirrhosis and HCC, preventive measures should be implemented. Therefore, the screening of HBV markers such as HBsAg, anti-HBc, AST/ALT, HBV DNA by nested-PCR or Real-time PCR should be performed for SLE patients prior to pretreatment and also during treatment periodically.

**Author Contribution Statement**

Study concept and design: Manoochehr Makvandi, Sedighheh Noormandi Pour, and Ali Teimoori; Analysis: Somayeh Shokri and interpretation of data: Shahab Mahmoudvand. And Somayeh Shokri and critical revision of the manuscript for important intellectual content: Elham Rajaee Statistical analysis: Shahab Mahmoudvand. Drafting of the manuscript: Somayeh Shokriand interpretation of data: Shahab Mahmoudvand. And Somayeh Shokri and also during treatment periodically.

**Acknowledgements**

**Funding statement**

This study with registration number OG-95119 was financially supported by Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

**Conflicts of interest**

The authors declare that there are no conflicts of interest.

**References**

Akcam FZ, Demir C (2005). Acute Hepatitis B Infection Due to Erythrocyte Suspension Obtained From ‘Anti-HBc Alone’ Positive Donor. *Transf Med*, 15, 61–2.

Alaviani SM, Farahnaz F, Kamran BL (2007). Comparison of seroepidemiology and transmission modes of viral hepatitis B in Iran and Pakistan. *Hepat Mon*, 7, 233–8.

Allain JP, Cox L (2011). Challenges in Hepatitis B Detection Among Blood Donors. *Curr Opin Hematol*, 18, 461–6.

Bessone F, Poles N, Roma MG (2014). Challenge of liver disease in systemic lupus erythematosus: clues for diagnosis and hints for pathogenesis. *World J Hepatol*, 6, 394–409.

Chen CY, Huang SX, Cheng A, et al (2015). High risk of hepatitis B reactivation among patients with acute myeloid leukemia. *PLoS One*, 10, e0126037.

Chen XX, Xiang KH, Zhang HP, et al (2020). Occult HBV infection in patients with autoimmune hepatitis: A virological and clinical study. *J Microbiol Immunol Infect*, 53, 946–54.

Candotti D, Assennato SM, Laperche S, Allain J, Levinck-Stezinar S (2019). Multiple HBV Transfusion Transmissions From Undetected Occult Infections: Revising the Minimal Infectious Dose. *Gut*, 68, 313–21.

Cholongitas E, Haidich AB, Apostolidou-Kioufi F, Chalevas P, Papanicolaou GV (2018). Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. *Ann Gastroenterol*, 31, 480–90.

Dandri M, Petersen J (2016). Mechanism of hepatitis B virus persistence in hepatocytes and its carcinogenic potential. *Clin Infect Dis*, 62, 281–8.

Fang J, Li W, Tan M, et al (2018). Effect of different hepatitis B infection status on the prognosis of active lupus nephritis treated with immunosuppression: a retrospective analysis of 177 patients. *Int J Rheum Dis*, 21, 1060–7.

Francis L, Perl A (2010). Infection in systemic lupus erythematosus: friend or foe?. *Int J Clin Rheumtol*, 5, 59–74.

Gish RG, Abdul Basit S, Ryan J, et al (2020). Correction to: Hepatitis B Core Antibody: Role in Clinical Practice in 2020. *Curr Hepatol Rep*, 19, 499.

Haghshenas MR, Arabi M, Mousavi T (2014). Hepatitis B genotypes in Iran. *Mater Sociomed*, 26, 129–33.

Hochberg MC (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*, 40, 1725.

Huang D, Aghdassi E, Su J, et al (2012). Prevalence and risk factors for liver biochemical abnormalities in Canadian patients with systemic lupus erythematosus. *J Rheumatol*, 39, 254–261.

Huang H, Li X, Zhu J, et al (2014). Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: A randomized clinical trial. *JAMA*, 312, 2521–30.

Hourfar MK, Walch LA, Geusendam G, et al (2009). Sensitivity and Specificity of Anti-HBc Screening Assays – Which Assay Is Best for Blood Donor Screening?. *Int J Lab Hematol*, 31, 649–56

Kuo MH, Tseng CW, Lee CH, et al (2020). Moderate risk of hepatitis B virus reactivation in HBsAg–/HBcAb+ carriers receiving rituximab for rheumatoid arthritis. *Sci Rep*, 10, 4566.

Kwak M-S, Kim YJ (2014). Occult hepatitis B virus infection. *World J Hepatol*, 6, 860–9.

Lin WT, Chen YM, Chen DY, et al (2018). Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. *Lupus*, 27, 66–75.

Lok AS, McMahon BJ (2009). Chronic hepatitis B: update 2009. *Hepatology*, 50, 661–2.

Mu Q, Zhang H, Luo XM. SLE (2015). another autoimmune disorder influenced by microbes and diet?. *Front Immunol*, 6, 608.
Manoochehr Makvandi et al

Makvandi M (2016). Update on occult hepatitis B virus infection. World J Gastroenterol, 22, 8720-34.

Matsumoto T, Marusawa H, Dogaki M, Sugimoto Y, Inokuma T (2010). Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver Int, 30, 1241–2.

Nour, H, Maroua C, Samir D (2022). A Study of the Relationship between Oxidative Stress and Risk of Developing Hepatocellular Carcinoma in People with Hepatitis B Infection; A Systematic Review Study. Asian Pac J Cancer Biol, 6, 316-20.

Ouyinkaa OO, Tong HV, Bui Tien S, et al (2005). Occult Hepatitis B Virus Infection in Nigerian Blood Donors and Hepatitis B Virus Transmission Risks. PLoS One, 10, 131–9.

Patel BB, Lipka S, Shen H, Davis-Yadle AH, Viswanathan P (2015). Establishing the link between hepatitis B virus infection and colorectal adenoma. J Gastrointest Oncol, 6, 492-7.

Paul S, Saxena A, Terrin N, et al (2016). Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med, 164, 30–40.

Radwan N, Abdelkhaliq H, Elgayar D, Elsharkawy M (2022). Study the Role of Cell Free DNA in the Diagnosis of Hepatocellular Carcinoma, an Egyptian Study. Asian Pac J Cancer Biol, 7, 3-8.

Raimondo G, Allain JP, Brunetto MR, et al (2008). Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol, 49, 652–7.

Raimondo G, Locarnini S, Pollicino T, et al (2019). Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol, 71, 397–408.

Roman S (2018). Occult Hepatitis B and other unexplored risk factors for Hepatocellular Carcinoma in Latin America. Ann Hepatol, 17, 541-3.

Rahman MA, Hakim F, Ahmed M, et al (2016). Prevalence of genotypes and subtypes of hepatitis B viruses in Bangladeshi population. Springer Plus, 5, 278.

Seed CR, Maloney R, Kiely P, et al (2015). Infectivity of Blood Components From Donors With Occult Hepatitis B Infection – Results From an Australian Look Back Programme. Vox Sang, 108, 113–22.

Simitik R, Pinho JR, Bertolini DA, et al (2004). Hepatitis B virus genotypes and precore and core mutants in Brazilian patients. J Clin Microbiol, 42, 2455-60.

Sosa-Jurado F, Meléndez-Mena D, Rosas-Murrieta NH, et al (2018). Effectiveness of PCR primers for the detection of occult hepatitis B virus infection in Mexican patients. PLoS One, 13, e020536.

Spredaico M, Berzuini A, Foglieni B, et al (2015). Poor efficacy of nucleic acid testing in identifying occult HBV infection and consequences for safety of blood supply in Italy. J Hepatol, 63, 1068–76.

Studier JA, Keppler KJ (1988). A note on the neighbor-joining algorithm of Saitou and Nei. Mol Biol Evol, 5, 729- 31.

Sumethkul K, Srivitidkul S. Prevalence of Chronic Hepatitis B Infection in Patients with Systemic Lupus Erythematosus: Viral Reactivation and Impact on Disease Activity. J Med Assoc Thai, 100, 124-30.

Taira R, Satake M, Momose S, et al (2013). Residual Risk of Transfusion Transmitted Hepatitis B Virus (HBV) Infection Caused by Blood Components Derived From Donors With Occult HBV Infection in Japan. Transfusion, 53, 1393–404.

Terrault NA, Lok ASF, McMahon BJ, et al (2018). Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 67, 1560-99.

Tsokos GC (2011). Systemic lupus erythematosus. N Engl J Med, 365, 2110–21.

Tordrup D, Huitin Y, Stenberg K, et al (2019). Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30. Lancet Global Health, 7, e1180-8.

Vermeulen M, Coleman C, Walker E, et al (2014). Transmission of Occult HBV Infection by ID-NAT Screened Blood. Vox Sang, 107, 146–8.

Wang S, Chen Y, Xu X, et al (2017). Prevalence of hepatitis B virus and hepatitis C virus infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Oncotarget, 8, 102437-45.

Watanabe R, Ishii T, Kobayashi H, et al (2014). Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey. Tohoku J Exp Med, 233, 129-33.

Yeo W, Johnson PJ (2006). Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology, 43, 209–20.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.